Redcare Pharmacy starts 2026 with a strong topline performance and a 58% increase of adj. EBITDA.
06.05.2026 - 06:30:03 | dgap.de| Redcare Pharmacy N.V. / Key word(s): Quarterly / Interim Statement 06.05.2026 / 06:30 CET/CEST The issuer is solely responsible for the content of this announcement. Group revenue increased 18.4% year over year in Q1, supported by growth in both, non-Rx and Rx. Non-Rx growth in Germany rebounded from 5% in Q4’25 to 9% in Q1’26, further accelerating to about 11% in April. Rx Germany continued strong momentum with 55.0% growth. Adjusted EBITDA reached 14.4 million, up 58% year over year. Adjusted EBITDA margin improved to 1.7% from 1.3% in Q1‘25. Full-year 2026 guidance confirmed. Sevenum, the Netherlands, May 6, 2026. Redcare Pharmacy started in 2026 with a strong first-quarter performance, combining revenue growth of 18.4% with an improvement of adjusted EBITDA margin by 0.4pp to 1.7%. Group revenue increased to EUR 849.5 million (Q1’25: EUR 717.3 million) supported by accelerating non-Rx growth in Germany and continued strong Rx momentum. In non-Rx, Group revenue increased by 10.2% year over year. In Germany, non-Rx growth re-accelerated to 9% year over year after only 5% in the previous quarter due to lapping effects. April trading confirms with about 11% year over year growth the rebound of the non-Rx business in Germany as sustained. Rx revenue continued to grow strongly in Q1 with an increase of 35.5% year over year across DACH. Rx revenue in Germany grew 55.0%, backed by continued improvement of e-Rx NPS to 76 (vs. 58 in Q1’25) and a steadily increasing adoption of e-prescriptions. The active customer base reached 14.2 million at the end of the quarter, an increase of 1.1 million year over year. Customer satisfaction remained high with an overall NPS of 75 and average shopping basket size increasing 9% year over year to EUR 68. Olaf Heinrich, CEO of Redcare Pharmacy, comments: “Q1 was a very good start of the year for us and confirms that we are executing on the priorities we set for 2026. We continue to improve the Rx customer journey, strengthen our customer proposition in non-Rx and invest in technology to build a scalable business that creates sustainable value for customers and shareholders.” Gross profit increased to EUR 178.0 million in Q1’26 (Q1’25: EUR 167.3 million). Gross profit margin was 21.0%, down from 23.3% in Q1’25 and stable vs. Q4 2025 (21.2%). The year-over-year decline is due to a competitive non-Rx environment, a higher Rx share and the impact of the Rx bonus introduced mid-September 2025. Rx accounted for 37% of total revenue, up from 33% in Q1’25. Adjusted selling and distribution expenses amounted to EUR 143.1 million in Q1’26 (Q1’25: EUR 139.3 million), equivalent to 16.8% of revenue (Q1’25: 19.4%). The improvement was supported by more efficient marketing spending and fixed cost leverage. Adjusted administrative expenses amounted to EUR 20.6 million, corresponding to 2.4% of revenue (Q1’25: EUR 19.2 million; 2.7%). Adjusted EBITDA increased to EUR 14.4 million in Q1’26 (Q1’25: EUR 9.1 million), corresponding to a margin of 1.7% (Q1’25: 1.3%). Improvements in the selling and distribution and administrative expense ratios more than offset the lower gross margin. The Q1 margin development was in line with seasonality and the company’s full-year guidance. Cash and short-term financial assets stood at EUR 135.0 million as of March 31, 2026 (December 31, 2025: EUR 203.5 million) after the redemption of EUR 64.5 million of the 2021/2028 convertible bonds during the quarter. Redcare Pharmacy confirms its guidance for full year 2026: total revenue growth of 13% to 15%, Rx revenue in Germany of more than EUR 670 million, total Group non-Rx revenue growth of 8% to 10%, and an adjusted EBITDA margin of at least 2.5%. Summary
06.05.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. View original content: EQS News | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Language: | English |
| Company: | Redcare Pharmacy N.V. |
| Erik de Rodeweg 11-13 | |
| 5975 WD Sevenum | |
| Netherlands | |
| Phone: | 0800 - 200 800 300 |
| Fax: | 0800 - 90 70 90 20 |
| E-mail: | investors@redcare-pharmacy.com |
| Internet: | www.redcare-pharmacy.com |
| ISIN: | NL0012044747, DE000A19Y072 |
| WKN: | A2AR94, A19Y072 |
| Indices: | MDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX |
| EQS News ID: | 2322006 |
| End of News | EQS News Service |
| |
So schätzen die Börsenprofis Redcare Pharmacy N.V. Aktien ein!
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen – dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren.
Für. Immer. Kostenlos.
Für. Immer. Kostenlos.
en | NL0012044747 | REDCARE PHARMACY N.V. | boerse | 69283785 |
